Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TXLYS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Tra-Exa-PSAR10
|
|||||
| Synonyms |
Tra Exa-PSAR10
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mal-Exa-PSAR10
|
Linker Info | ||||
| Conjugate Type |
Drug-linker was conjugated to the native inter-chain cysteines of reduced trastuzumab following a straightforward bioconjugation protocol in order to obtain homogeneous DAR 8.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.